Paper Details

  1. Home
  2. Paper Details

The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.

Author: BiancoAssunta, BiolatoMarco, GasbarriniAntonio, GriecoAntonio, LucchiniMatteo, MirabellaMassimiliano

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review analyzes pre-registration and post-marketing data on hepatotoxicity of disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis. While rare, serious liver adverse events have been reported for several DMTs. Patients should be informed about potential hepatic side effects and monitored for clinical symptoms of liver injury.
Paper Details　
Original Abstract of the Article :
In this narrative review, we analyze pre-registration and post-marketing data concerning hepatotoxicity of all disease-modifying therapies (DMTs) available for the treatment of relapsing-remitting multiple sclerosis, including beta interferon, glatiramer acetate, fingolimod, teriflunomide, dimethyl ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354931/

データ提供：米国国立医学図書館（NLM）

Disease-Modifying Therapies for Multiple Sclerosis: Navigating the Desert of Liver Injury

Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system. Disease-modifying therapies (DMTs) are used to slow the progression of the disease and reduce the frequency and severity of relapses. However, some DMTs have been associated with liver injury. This study reviews the hepatotoxicity of various DMTs used to treat relapsing-remitting MS. The authors discuss the different types of liver injury, the proposed mechanisms of action, and the risk factors associated with each DMT. This study provides valuable information for healthcare professionals to make informed decisions about the use of DMTs in patients with MS, considering the potential risks and benefits.

A Journey Through the Desert of Liver Injury

This study takes a close look at the potential liver toxicity of various DMTs used to treat MS. It highlights the importance of careful patient selection, monitoring for liver injury, and considering alternative treatments when necessary. The authors emphasize that while serious liver adverse events are rare, they can occur, and it's essential for healthcare professionals to be aware of the risks and to monitor their patients closely. It's a reminder that even in the seemingly safe desert of MS treatment, there can be hidden dangers and potential side effects that require careful attention and management.

A Guide Through the Desert of DMTs

This research provides a valuable guide for navigating the potential for liver injury associated with DMTs used to treat MS. It highlights the importance of careful patient selection, monitoring for liver injury, and considering alternative treatments when necessary. It's a reminder that even in the seemingly safe desert of MS treatment, there can be hidden dangers and potential side effects that require careful attention and management.

Dr.Camel's Conclusion

This study highlights the importance of carefully considering the potential for liver injury when using DMTs to treat MS. It provides valuable information for healthcare professionals to make informed decisions about the use of DMTs in their patients, considering the individual needs and risk factors of each patient. It's like having a skilled guide to navigate the desert of DMTs, ensuring a safer and more effective treatment journey for all patients.

Date :
  1. Date Completed 2022-02-03
  2. Date Revised 2022-02-03
Further Info :

Pubmed ID

34319570

DOI: Digital Object Identifier

PMC8354931

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.